Literature DB >> 14991932

Anti-liver cancer activity of TNF-related apoptosis-inducing ligand gene and its bystander effects.

Chao He1, Wei-Feng Lao, Xiao-Tong Hu, Xiang-Ming Xu, Jing Xu, Bing-Liang Fang.   

Abstract

AIM: To observe the anti-liver cancer activity of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene and its bystander effects on hepatocellular carcinoma (HCC) cell line SMMC7721.
METHODS: Full-length cDNA of human TRAIL was transferred into SMMC7721 cells with a binary adenoviral vector system. Polymerase-chain reaction following reverse transcription (RT-PCR) was used to determine the expression of TRAIL gene. Effects of the transfected gene on proliferation of SMMC7721 cells were measured by MTT assay. Its influence on apoptosis was demonstrated by fluorescence-activated cell sorting (FACS). The bystander effect was observed by co-culturing the SMMC7721 cells with and without the transfected TRAIL gene at different ratios, and the culture medium supernatant from the transfected cells was also examined for its influence on SMMC7721 cells.
RESULTS: The growth-inhibition rate and apoptotic cell fraction in the cells transfected with the TRAIL gene, Bax gene or only LacZ gene were 91.2%, 48.0%, 28.8% and 29.1%, 12.5%, 6.6%, respectively. The growth-inhibition rate of transfection with these three sequences in normal human fibroblasts was 6.1%, 45.5% and 7.6%, respectively, indicating a discriminative inhibition of TRAIL transfection on the cancer cells. In the co-culturing test, addition of the transfected TRAIL to SMMC7721 cells in proportions of 5%, 25%, 50%, 75% and 100%, resulted in a growth-inhibition of 15.9%, 67%, 80.2%, 86.4% and 87.7%, respectively. We failed to observe a significant growth-inhibition effect of the culture medium supernatant on SMMC7721 cells.
CONCLUSION: TRAIL gene transferred by a binary adenoviral vector system can inhibit proliferation of SMMC7721 cells and induce their apoptosis. A bystander effect was observed, which seemed not to be mediated by soluble factors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14991932      PMCID: PMC4716903          DOI: 10.3748/wjg.v10.i5.654

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  40 in total

1.  Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene.

Authors:  S Kagawa; C He; J Gu; P Koch; S J Rha; J A Roth; S A Curley; L C Stephens; B Fang
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

2.  Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes.

Authors:  M Leverkus; M Neumann; T Mengling; C T Rauch; E B Bröcker; P H Krammer; H Walczak
Journal:  Cancer Res       Date:  2000-02-01       Impact factor: 12.701

3.  Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.

Authors:  J P Sheridan; S A Marsters; R M Pitti; A Gurney; M Skubatch; D Baldwin; L Ramakrishnan; C L Gray; K Baker; W I Wood; A D Goddard; P Godowski; A Ashkenazi
Journal:  Science       Date:  1997-08-08       Impact factor: 47.728

4.  The receptor for the cytotoxic ligand TRAIL.

Authors:  G Pan; K O'Rourke; A M Chinnaiyan; R Gentz; R Ebner; J Ni; V M Dixit
Journal:  Science       Date:  1997-04-04       Impact factor: 47.728

5.  TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling.

Authors:  G Pan; J Ni; G Yu; Y F Wei; V M Dixit
Journal:  FEBS Lett       Date:  1998-03-06       Impact factor: 4.124

6.  Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family.

Authors:  R M Pitti; S A Marsters; S Ruppert; C J Donahue; A Moore; A Ashkenazi
Journal:  J Biol Chem       Date:  1996-05-31       Impact factor: 5.157

7.  Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions.

Authors:  D Lawrence; Z Shahrokh; S Marsters; K Achilles; D Shih; B Mounho; K Hillan; K Totpal; L DeForge; P Schow; J Hooley; S Sherwood; R Pai; S Leung; L Khan; B Gliniak; J Bussiere; C A Smith; S S Strom; S Kelley; J A Fox; D Thomas; A Ashkenazi
Journal:  Nat Med       Date:  2001-04       Impact factor: 53.440

Review 8.  TRAIL: a molecule with multiple receptors and control mechanisms.

Authors:  T S Griffith; D H Lynch
Journal:  Curr Opin Immunol       Date:  1998-10       Impact factor: 7.486

9.  Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.

Authors:  M M Keane; S A Ettenberg; M M Nau; E K Russell; S Lipkowitz
Journal:  Cancer Res       Date:  1999-02-01       Impact factor: 12.701

10.  Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA.

Authors:  S A Marsters; R M Pitti; C J Donahue; S Ruppert; K D Bauer; A Ashkenazi
Journal:  Curr Biol       Date:  1996-06-01       Impact factor: 10.834

View more
  3 in total

1.  TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5.

Authors:  Ching-Huang Wu; Ching-Hai Kao; Ahmad R Safa
Journal:  Hum Gene Ther       Date:  2008-07       Impact factor: 5.695

Review 2.  Discovery and clinical introduction of first-in-class imipridone ONC201.

Authors:  Joshua E Allen; C Leah B Kline; Varun V Prabhu; Jessica Wagner; Jo Ishizawa; Neel Madhukar; Avital Lev; Marie Baumeister; Lanlan Zhou; Amriti Lulla; Martin Stogniew; Lee Schalop; Cyril Benes; Howard L Kaufman; Richard S Pottorf; B Rao Nallaganchu; Gary L Olson; Fahd Al-Mulla; Madeleine Duvic; Gen Sheng Wu; David T Dicker; Mala K Talekar; Bora Lim; Olivier Elemento; Wolfgang Oster; Joseph Bertino; Keith Flaherty; Michael L Wang; Gautam Borthakur; Michael Andreeff; Mark Stein; Wafik S El-Deiry
Journal:  Oncotarget       Date:  2016-11-08

3.  Mitomycin C induces bystander killing in homogeneous and heterogeneous hepatoma cellular models.

Authors:  Ratna Kumari; Aanchal Sharma; Amrendra Kumar Ajay; Manoj Kumar Bhat
Journal:  Mol Cancer       Date:  2009-10-21       Impact factor: 27.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.